Eli Lilly announced a $3.5 billion investment to build a new manufacturing campus in Lehigh Valley, Pennsylvania, dedicated to next‑generation obesity injectables and associated devices, including anticipated production of retatrutide. The facility will scale commercial supply and support Lilly’s expanding obesity franchise. Lilly said the plant will produce injectables and devices, positioning the company to control end‑to‑end manufacture for high‑volume weight‑loss biologics. The investment reflects strategic planning for anticipated demand and the need to secure domestic capacity amid global supply constraints. The project underscores how leading biopharma companies are vertically investing in manufacturing to support high‑growth therapeutic categories — particularly obesity — where production scale and device integration are decisive commercial factors.